Reference : Pharmacogenetics of infliximab in Crohn's disease
Scientific journals : Article
Human health sciences : Surgery
http://hdl.handle.net/2268/25881
Pharmacogenetics of infliximab in Crohn's disease
English
Dideberg, Vinciane [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
Bours, Vincent [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Génétique générale et humaine]
2007
Acta Endoscopica
Endoscopica
37
4
521-530
Yes
International
0240-642X
Nancy
[en] Crohn's disease ; infliximab ; pharmacogenetics
[en] Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects.
http://hdl.handle.net/2268/25881

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Pharmacogenetics of infl... Acta end 2007 521-530.pdfPublisher postprint256.97 kBRequest copy
Open access
PostpAutAO-Pharmacogenetics of infliximab in... 2007-Acta End traité OCR.pdfAuthor postprint213.74 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.